Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled 4-week trial of fluticasone propionate + albuterol sulfate inhalation powder in adolescents and adults with asthma
MOH_2025-04-01_014014Phase 3Not yet recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate and salbutamol in asthma (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
fluticasone propionatesalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2025-04-01_014014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-01_014014.